HC Wainwright Cuts REGENXBIO (NASDAQ:RGNX) Price Target to $30.00

REGENXBIO (NASDAQ:RGNX) had its price objective reduced by HC Wainwright from $32.00 to $30.00 in a report released on Monday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for REGENXBIO’s Q1 2026 earnings at ($1.23) EPS, Q2 2026 earnings at ($1.23) EPS, Q3 2026 earnings at $0.31 EPS, Q4 2026 earnings at ($1.24) EPS and FY2026 earnings at ($3.38) EPS.

Several other research analysts have also recently weighed in on RGNX. Leerink Partners lifted their price target on REGENXBIO from $16.00 to $20.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. Chardan Capital decreased their target price on shares of REGENXBIO from $52.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, February 10th. UBS Group reissued an “overweight” rating and set a $18.00 price target on shares of REGENXBIO in a report on Tuesday, February 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of REGENXBIO in a research report on Thursday, January 22nd. Finally, Robert W. Baird set a $27.00 target price on REGENXBIO in a research report on Tuesday, February 10th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $27.50.

REGENXBIO Price Performance

NASDAQ:RGNX opened at $9.38 on Monday. The firm has a market capitalization of $484.10 million, a P/E ratio of -2.49 and a beta of 1.08. The company’s fifty day moving average price is $11.21 and its 200-day moving average price is $11.45. REGENXBIO has a 1-year low of $5.03 and a 1-year high of $16.19.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings results on Thursday, March 5th. The biotechnology company reported ($1.30) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.29). The business had revenue of $30.34 million during the quarter, compared to analysts’ expectations of $45.48 million. REGENXBIO had a negative net margin of 113.75% and a negative return on equity of 103.12%. Equities analysts anticipate that REGENXBIO will post -4.84 EPS for the current fiscal year.

Hedge Funds Weigh In On REGENXBIO

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RGNX. State of Alaska Department of Revenue purchased a new stake in shares of REGENXBIO during the third quarter worth about $25,000. Aquatic Capital Management LLC acquired a new stake in REGENXBIO in the 3rd quarter worth about $37,000. Jones Financial Companies Lllp increased its stake in REGENXBIO by 44.4% during the 3rd quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock worth $40,000 after buying an additional 1,270 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its position in shares of REGENXBIO by 754.1% in the second quarter. Steward Partners Investment Advisory LLC now owns 5,663 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Captrust Financial Advisors purchased a new position in shares of REGENXBIO in the second quarter valued at approximately $85,000. 88.08% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO News Summary

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Interim AFFINITY data show continued functional improvement and a clean safety profile at the pivotal dose—cardiac MRI stability at 1 year, functional measures exceeded external controls (including in patients aged 8+), and liver‑safety markers were supportive; company says pivotal topline data expected Q2 2026. REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE TRIAL OF RGX‑202
• Positive Sentiment: Independent reporting (Reuters) corroborates company claims: early‑to‑mid stage trial showed improved muscle function and a favorable safety profile, which supports the therapeutic and regulatory narrative for RGX‑202. Regenxbio’s Duchenne gene therapy shows improved muscle function in trial
• Neutral Sentiment: Market reaction was mixed: some outlets note progress but frame headlines as “mixed signals” because strong clinical readouts coexist with other headwinds. This explains why positive data did not produce an unambiguous rally. Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals
• Neutral Sentiment: HC Wainwright updated model assumptions: reduced near‑term EPS estimates but kept a Buy rating and $30 target while adjusting later‑year estimates higher — a sign analysts still see upside but expect short‑term cost/earnings pressure. HC Wainwright estimate changes (MarketBeat summary)
• Neutral Sentiment: RBC Capital reaffirmed its Buy rating, which supports longer‑term sentiment among some institutional analysts despite near‑term volatility. RBC Capital Reaffirms Their Buy Rating on RegenXBio (RGNX)
• Negative Sentiment: Multiple law firms have filed or are soliciting clients for securities class actions covering a broad period through Jan 27, 2026; active litigation risk and potential settlements or disclosures are ongoing negative catalysts. RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP
• Negative Sentiment: Additional plaintiff firms (Levi & Korsinsky, Pomerantz, Rosen, Schall, Gross, Rosen) have issued notices—heightening litigation visibility and potential legal costs or management distraction. Levi & Korsinsky investor notice

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.